1. ‘Real-World’ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey 
Gregory Y.H. Lip, MD, Cécile Laroche, MSc, Gheorghe-Andrei Dan, MD, Massimo Santini, MD, Zbigniew Kalarus, MD, Lars Hvilsted Rasmussen, MD, Popescu Mircea Ioachim, MD, Otilia Tica, MD, Giuseppe Boriani, MD, Paolo Cimaglia, MD, Igor Diemberger, MD, Camilla Fragtrup Hellum, MD, Bettina Mortensen, MD, Aldo P. Maggioni, MD 
The American Journal of Medicine 
Volume 127, Issue 6, Pages e1 (June 2014)
DOI: /j.amjmed
Copyright © 2014 Elsevier Inc. Terms and Conditions

2. Figure 1
Antithrombotic drug prescription at inclusion and discharge when the following interventions were performed at the time of the survey or planned at discharge: pharmacologic cardioversion (A), electrical cardioversion (B), or catheter ablation (C). AP = antiplatelet; OAC = oral anticoagulation.
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2014 Elsevier Inc. Terms and Conditions